Compare DoorDash Inc (DASH) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Medpace Holdings Inc — how do they compare? DoorDash Inc trades at $196.62 (market cap $83.07B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: DoorDash Inc is far larger — about 4.9× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Medpace Holdings Inc for 14 Days on average.
| DASH | MEDP | |
|---|---|---|
Market Cap | $83.07B | $16.82B |
Volume | 3,242,567 | 223,093 |
Sector | Media | Health |
52-Week High | $275.44 | $630.19 |
52-Week Low | $146.60 | $393.42 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $81.03B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $196.33, up 2.66% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent developments include AI-powered text ordering and drone delivery expansion. Analyst consensus remains strongly bullish with 75% buy ratings and a $255.80 price target, representing 30% upside potential from current levels.
The outlook remains positive with continued revenue growth projected to $15.9B in 2026, though net income may moderate to $841M. Key risks include competitive pressures, regulatory scrutiny from ongoing investigations, and execution challenges in new initiatives. The stock trades at premium valuations (P/E 100.37) requiring sustained growth to justify current levels.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
